sig

Full identifier: http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#sig

Searching for classes... Loading...

Searching for instances... Loading...

Searching for templates... Loading...

Minted in Nanopublication

 RAYpxq5rXv comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAYpxq5rXv...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "therapy with lipid altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate ezetimibe tablets are an inhibitor of intestinal cholesterol and related phytosterol absorption indicated as an adjunct to diet to reduce elevated total c ldl c apo b and non hdl c in patients with primary hyperlipidemia alone or in combination with an hmg coa reductase inhibitor statin 1 1 reduce elevated total c ldl c apo b and non hdl c in patients with mixed hyperlipidemia in combination with fenofibrate 1 1 reduce elevated total c and ldl c in patients with homozygous familial hypercholesterolemia hofh in combination with atorvastatin or simvastatin 1 2 reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia phytosterolemia 1 3 limitations of use 1 4 the effect of ezetimibe tablets on cardiovascular morbidity and mortality has not been determined ezetimibe tablets have not been studied in fredrickson type i iii iv and v dyslipidemias monotherapy ezetimibe tablets administered alone are indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol total c low density lipoprotein cholesterol ldl c apolipoprotein b apo b and non high density lipoprotein cholesterol non hdl c in patients with primary heterozygous familial and non familial hyperlipidemia combination therapy with hmg coa reductase inhibitors statins ezetimibe tablets administered in combination with a 3 hydroxy 3 methylglutaryl coenzyme a hmg coa reductase inhibitor statin is indicated as adjunctive therapy to diet for the reduction of elevated total c ldl c apo b and non hdl c in patients with primary heterozygous familial and non familial hyperlipidemia combination therapy with fenofibrate ezetimibe tablets administered in combination with fenofibrate are indicated as adjunctive therapy to diet for the reduction of elevated total c ldl c apo b and non hdl c in adult patients with mixed hyperlipidemia ezetimibe tablets administered in combination with fenofibrate are indicated as adjunctive therapy to diet for the reduction of elevated total c ldl c apo b and non hdl c in adult patients with mixed hyperlipidemia the combination of ezetimibe tablets and atorvastatin or simvastatin is indicated for the reduction of elevated total c and ldl c levels in patients with hofh as an adjunct to other lipid lowering treatments e g ldl apheresis or if such treatments are unavailable ezetimibe tablets are indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia the effect of ezetimibe tablets on cardiovascular morbidity and mortality has not been determined ezetimibe tablets have not been studied in fredrickson type i iii iv and v dyslipidemias" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAYpxq5rXv... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T11:44:22.258+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAYpxq5rXv... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAYpxq5rXv... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAYpxq5rXv... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAYpxq5rXv...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAYpxq5rXv... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAYpxq5rXv...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 3 Jul 2021, 09:44:22 UTC

References

Loading...

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)